CMS Proposes 2027 Medicare Advantage Rule; Drug Price Negotiations Advance

Alston & Bird's Health Care Week in Review provides a concise update on recent developments in U.S. health care regulations and policies. The latest issue highlights the CMS proposed rule for the 2027 Medicare Advantage and Part D programs, signalling forthcoming regulatory changes in Medicare coverage and prescription drug benefits. Additionally, the report covers the announcement of negotiated drug prices for fifteen medications under the second round of the Medicare Drug Price Negotiation Program, indicating ongoing efforts to manage drug costs within federal health programs.